Table 1

Overview of the patients in the lipidomic cohort

Normal controlHealthy obeseNAFLEarly NASHNASH
Age70.5 (63.5–74)43.5 (35.3–48.0)43 (34–52.5)44 (34–51)46.5 (35–51.2)
BMI24.6 (21.7–26.3)48.9 (44.3–52.5)47.8 (42.2–52.7)50.4 (44.2–54.1)55.2 (49.6–59.2)
Sex % male506.534.637.721.8
Fat (area in %)≤5≤5>5>5>5
NAS score0 (0–0)0 (0–0)1 (1–2)3 (2–3)5 (5–6)
NAS fat0 (0–0)0 (0–0)1 (1–2)2 (1–2)3 (3–3)
NAS ballooning0 (0–0)0 (0–0)0 (0–0)0 (0–0)1 (1–1)
NAS inflammation0 (0–0)0 (0–0)0 (0–0)1 (1–1)1 (1–1.25)
Fibrosis0 (0–0)0 (0–0)0 (0–1)1 (0–1)1 (1–1)
NAFLD without fibrosis
(CC/CT/TT)
NANA30/49/139/10/61/4/2
NAFLD with fibrosis (CC/CT/TT)NANA11/22/1013/7/47/13/3
Total MBOAT7 rs641738 (CC/CT/TT) (n=280)10/14/613/17/641/71/2322/17/108/17/5
  • Patients are grouped by histology using the NAS score as the main classification criteria. Values are given as median with IQR in parentheses. Additional information is provided in online supplementary tables 8 and 9.

  • BMI, body mass index; MBOAT7, membrane-bound O-acyltransferase domain containing 7; NA, not applicable; NAFLD, non-alcoholic fatty liver disease; NAS, NAFLD Activity Score; NASH, non-alcoholic steatohepatitis.